• Lymph nodes ≥1.5 cm in the greatest transverse diameter or 1.1 to 1.5 cm in longest axis and >1.0 cm in the short axis
• Must be able to obtain 1 suitable, fresh excisional biopsy
• Patients who have had high-dose with with stem-cell rescue or ineligible for high-dose with stem-cell rescue
• Transplantation does not exclude pt from study

Astra Zeneca CBCI-234

A Randomised Double Blind Phase II Trial to Evaluate the Efficacy of Two Doses of Fostamatinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

• Only for patients that have been previously treated with SGN35, and had disease progression or relapse after discontinuing treatment in the prior SGN-35 study

SGN35-006 CBCI-195

Treatment with SGN-35 in Patients with Hematologic Malignancies Who Have Previously Participated in a SGN-35 Study

• Only open to patients with Hepatic Impairment - Bilirubin > 2 mg/dL
• Must be CD30+

SGN35-008 CBCI-194

An Open-Label Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35) in Patients with CD30-Positive Hematologic Malignancies

• Bidimensionally measurable disease of at least 1.5 cm
• Patients who have been treated with single agent rituximab or corticosteroids as monotherapy are excluded.
• No ALCL
• Must be CD30+

SGN35-012 CBCI-223

A Phase 2 study of Brentuximab Vedotin in Relapsed or Refractory CD30-positive Non-Hodgkin Lymphoma (NHL)

• Have a hematologic malignancythat is expected to express the CD22 antigen for which no effective standard therapy exists.
• Must have at least on bi-dimensionally measurable lesion ≥ 1.5 cm.

Genentech CBCI-210

An Open-Label, Multicenter, Phase I Trial of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia